Armata Pharmaceuticals (ARMP) Key Ratios

$5.45

up-down-arrow $-2.91 (-34.81%)

As on 03-Sep-2026 15:37EDT

Market cap

info icon

$190 Mln

Revenue (TTM)

info icon

$6 Mln

P/E Ratio

info icon

--

P/B Ratio

info icon

2.1

Div. Yield

info icon

0 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue 218.12 15.72 -19.29 10.00 12.87
EBIT 173.57 746.87 -1,312.31 -237.87 -239.09
Net Profit 164.28 554.99 -647.57 -247.34 -243.00
EPS 137.85 365.43 -728.90 -258.30 -225.66
Book Value -- -- -- -- --
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMDec-25Dec-24
EBIT-Margin info -1,610.08-1,203.21-3,081.45-3,205.73-157.98
Net Margin info ---558.57-3,467.04----
Return on equity info -1,087.25-697.30--130.3747.24
Return on Capital info -112.47-87.15---234.99-22.68
Return on Assets info -100.09-76.84-120.87-212.83-20.47
Debt to Equity (x) info ----0.00-1.32-2.63
ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Armata Pharmaceuticals (ARMP)
--
-234.99
-22.68
-79.73
-49.79
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

--

--

Profit after tax / Average Net worth * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Armata Pharmaceuticals (ARMP)
--
130.37
47.24
-3,439.35
-120.10
Peer Median
-40.40
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

-120.87

Lower than Peers by 89.89

Profit after tax / Average Total assets * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Armata Pharmaceuticals (ARMP)
-120.87
-212.83
-20.47
-66.96
-41.56
Peer Median
-30.98
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

-3,081.45

Lower than Peers by 2,997.84

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Armata Pharmaceuticals (ARMP)
-3,081.45
-3,205.73
-157.98
-1,466.53
-669.72
Peer Median
-83.62
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

-3,467.04

Lower than Peers by 3,374.37

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Armata Pharmaceuticals (ARMP)
-3,467.04
-3,544.03
-365.60
-1,524.51
-666.73
Peer Median
-92.67
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Profit Margin

0.00

Lower than Peers by 0.00

(Net profit + Depreciation) / Gross Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Armata Pharmaceuticals (ARMP)
0.00
--
--
--
--
Peer Median
0.00
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Revenue Growth

-19.29

Lower than Peers by 73.25

Year on year growth in net sales

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Armata Pharmaceuticals (ARMP)
-19.29
-0.05
0.14
-0.18
0.23
Peer Median
53.95
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

-1,312.31

Lower than Peers by 1,311.51

Year on year growth in operating profit (EBIT)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Armata Pharmaceuticals (ARMP)
-1,312.31
-1,823.28
87.69
-80.06
-59.75
Peer Median
-0.80
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

-647.57

Lower than Peers by 640.27

Year on year growth in profit after tax

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Armata Pharmaceuticals (ARMP)
-647.57
-818.79
72.60
-87.03
-59.43
Peer Median
-7.30
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

-728.90

Lower than Peers by 743.55

Year on year growth in earnings per share

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Armata Pharmaceuticals (ARMP)
-728.90
-13.94
0.83
-0.87
-0.16
Peer Median
14.65
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

-94.04

Lower than Peers by 83.86

Year on year growth in book value per share

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Armata Pharmaceuticals (ARMP)
-94.04
--
--
--
--
Peer Median
-10.18
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Debt to Equity

--

--

Total debt / Net worth

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Armata Pharmaceuticals (ARMP)
--
-1.32
-2.63
-3.75
1.35
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

-1.06

--

(Short term borrowings / Net worth)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Armata Pharmaceuticals (ARMP)
-1.06
-0.02
-0.90
-0.30
0.47
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

0.11

Lower than Peers by 5.70

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Armata Pharmaceuticals (ARMP)
0.11
1.19
0.23
1.16
1.09
Peer Median
5.81
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

0.11

Lower than Peers by 5.59

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Armata Pharmaceuticals (ARMP)
0.11
--
--
--
--
Peer Median
5.70
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

-7.99

Lower than Peers by 5.90

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Armata Pharmaceuticals (ARMP)
-7.99
-9.48
-0.76
-25.29
-1,272.00
Peer Median
-2.09
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

45.68

Higher than Peers by 26.54

Debtors outstanding / Net Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Armata Pharmaceuticals (ARMP)
45.68
9.62
14.38
74.25
154.88
Peer Median
19.14
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

0.03

Lower than Peers by 0.03

Sales / Average Total Assets

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Armata Pharmaceuticals (ARMP)
0.03
0.06
0.06
0.04
0.06
Peer Median
0.06
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Armata Pharmaceuticals (ARMP)
--
45.28
144.96
479.61
381.96
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Armata Pharmaceuticals (ARMP)
--
--
--
--
-31.18
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Armata Pharmaceuticals (ARMP)
--
201.23
12.47
613.07
14.69
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Armata Pharmaceuticals (ARMP)
--
--
--
--
336.10
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Earnings

--

--

Current share price divided by earning per share in the last twelve months

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Armata Pharmaceuticals (ARMP)
--
-1.31
-5.78
-1.69
-1.21
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Book Value

2.11

Lower than Peers by 3.07

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Armata Pharmaceuticals (ARMP)
2.11
-1.04
-2.28
-3.65
1.24
Peer Median
5.18
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

--

--

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Armata Pharmaceuticals (ARMP)
--
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

14.44

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Armata Pharmaceuticals (ARMP)
14.44
-3.26
-33.07
-3.42
-2.19
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

190

Higher than Peers by 44

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Armata Pharmaceuticals (ARMP)
190
--
--
--
--
Peer Median
146
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...